Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Ivermectin  COVID-19 treatment studies for Ivermectin  C19 studies: Ivermectin  Ivermectin   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
Effect of Ivermectin 600 mcg/kg for 6 days vs Placebo on Time to Sustained Recovery in Outpatients with Mild to Moderate COVID-19: A Randomized Clinical Trial
Naggie et al., medRxiv, doi:10.1101/2022.12.15.22283488 (Preprint), NCT04885530 (history)
Naggie et al., Effect of Ivermectin 600 mcg/kg for 6 days vs Placebo on Time to Sustained Recovery in Outpatients with Mild.., medRxiv, doi:10.1101/2022.12.15.22283488 (Preprint), NCT04885530
Dec 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Results for the 600µg/kg arm of ACTIV-6. See [Naggie].
Naggie et al., 15 Dec 2022, Double Blind Randomized Controlled Trial, placebo-controlled, USA, preprint, 29 authors, trial NCT04885530 (history).
Contact: susanna.naggie@duke.edu.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperIvermectinAll
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2022.12.15.22283488; this version posted December 15, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. 1 Effect of Ivermectin 600 µg/kg for 6 days vs Placebo on Time to Sustained Recovery in Outpatients with Mild to Moderate COVID-19: A Randomized Clinical Trial Susanna Naggie, MD, MHS,1,2 David R. Boulware, MD, MPH,3 Christopher J. Lindsell, PhD,4 Thomas G. Stewart, PhD,5 Stephen C. Lim, MD,6 Jonathan Cohen, MD,7 David Kavtaradze, MD,8 Arch P. Amon, MD,9 Ahab Gabriel, MD,10 Nina Gentile, MD,11 G. Michael Felker, MD, MHS,1,2 Russell L. Rothman, MD, DPP,4 Dushyantha Jayaweera, MD,12 Matthew W. McCarthy, MD,13 Mark Sulkowski, MD,14 Sybil Wilson, RN,1 Allison DeLong, BS,1 April Remaly, BA,1 Rhonda Wilder, MS,1 Sean Collins, MD, MSci,4,15 Sarah E. Dunsmore, PhD,16 Stacey J. Adam, PhD,17 Florence Thicklin,18 George J. Hanna, MD,19 Adit A. Ginde, MD, MPH,20 Mario Castro, MD, MPH,21 Kathleen McTigue, MD, MPH, MS,22 Elizabeth Shenkman, PhD,23 Adrian F. Hernandez, MD, MHS1,2 for the Accelerating Covid-19 Therapeutic Interventions and Vaccines (ACTIV)-6 Study Group and Investigators 1 Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC; 2 Department of Medicine, Duke University School of Medicine, Durham, NC; 3Division of Infectious Diseases and International Medicine, University of Minnesota, Minneapolis, MN; 4 University Medical Center, Nashville, TN; 5School of Data Science, University of Virginia, Charlottesville, VA; 6University Medical Center New Orleans, Louisiana State University Health Sciences Center, New Orleans, LA; 7Jadestone Clinical Research, LLC, Silver Spring, MD; 8 David Kavtaradze, MD, Inc., Cordele, GA; 9Lakeland Regional Medical Center, Lakeland, FL; 10 Focus Clinical Research Solutions, Charlotte, NC; 11Department of Emergency Medicine, Lewis Katz School of Medicine at Temple University, Philadelphia, PA; 12Department of NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2022.12.15.22283488; this version posted December 15, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. 2 Medicine, Miller School of Medicine, University of Miami, Miami, FL; 13Weill Cornell Medicine, New York, NY; 14Division of Infectious Diseases, Johns Hopkins University, Baltimore, MD; 15Veterans Affairs Tennessee Valley Healthcare System, Geriatric Research, Education and Clinical Center (GRECC), Nashville, TN; 16National Center for Advancing Translational Sciences, Bethesda, MD; 17Foundation for the National Institutes of Health, Bethesda, MD; 18Stakeholder Advisory Committee, Pittsburgh, PA; 19Biomedical Advanced Research and Development Authority, Washington, DC; 20University of Colorado School of Medicine, Aurora, CO; 21Division of Pulmonary, Critical Care and Sleep Medicine, University of Missouri-Kansas City School of Medicine, Kansas City, KS; 22Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA; 23Department of Health Outcomes..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit